Biotech’s double standard on biogenerics

Biotech’s double standard on biogenerics

(UPDATED: See below.)

Yesterday, the WSJ Health Blog cited a WSJ story as evidence that “biogenerics” — that is, generic versions of biotech drugs, which currently don’t exist — need to be treated with caution. Unfortunately, that post missed a much more important point about biogenerics: The… Continue Reading

Ceregene: Catching an updraft in gene therapy

Ceregene: Catching an updraft in gene therapy

(UPDATED: See below.)

Ceregene, a San Diego biotech at work on a gene therapy for Parkinson’s disease, has so far raised $28 million in a third funding round and last week struck a development partnership with Genzyme that resulted in a $25 million up-front payment and potential… Continue Reading

Applied Genetic Technologies gets $2M for gene therapy

Applied Genetic Technologies, an Alachua, Fla., gene-therapy developer, received a $2 million milestone payment from Genzyme.

The two companies are jointly developing a gene therapy for treating a form of blindness called age-related macular degeneration. The treatment uses an adeno-associated virus designed to deliver a… Continue Reading

Amicus Therapeutics aims for potentially disruptive $92M IPO

Amicus Therapeutics aims for potentially disruptive $92M IPO

Amicus Therapeutics, a Cranbury, N.J., developer of drugs to treat rare genetic diseases, said it plans to raise as much as $92 million in an IPO — money that would fund its pursuit of new drugs for rare genetic diseases, a strategy could be disruptive… Continue Reading